This is a multi-center evaluation of NGM621 in an open-label, single-dose and multiple-dose escalation study in participants with Geographic Atrophy secondary to Age-related Macular Degeneration.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
15
NGM Clinical Study Site
Arcadia, California, United States
NGM Clinical Study Site
Newport Beach, California, United States
NGM Clinical Study Site
Melbourne, Florida, United States
NGM Clinical Study Site
St. Petersburg, Florida, United States
Incidence and Severity of Ocular and Systemic Treatment-Emergent Adverse Events (TEAEs)
The number and percent of patients reporting treatment emergent adverse events (TEAEs) by cohort.
Time frame: 12 weeks
Serum Concentration of NGM621
Individual and mean serum NGM621 concentration data by cohort.
Time frame: 12 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
NGM621 Dose 4
NGM Clinical Study Site
Austin, Texas, United States
NGM Clinical Study Site
The Woodlands, Texas, United States